Please assess the completion status of the following clinical trial:

Trial Title: Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Admission to MD Anderson Cancer Center Surgical Intensive Care Unit (SICU) under the Thoracic Surgery physician group~2. Intravenous vancomycin therapy deemed necessary~Exclusion Criteria:~1. Age less than 18 years~2. History of hypersensitivity to vancomycin~3. Patient weight greater than 150 kg~4. Receival of 1 or more doses of the following agents within 72 hours prior to screening: amphotericin B (lipid, liposomal, or conventional formulation), aminoglycosides, foscarnet and/or intravenous contrast dye.~5. Prior exposure (within 7 days) to intravenous vancomycin~6. Current renal insufficiency defined as baseline Scr \>/= 1.5 mg/dL, or increase in baseline serum creatinine (SCr) by \>/= 0.5 mg/dL within the last 2 days, or estimated creatinine clearance (CrCl) \</= 30 mL/min by Cockcroft-Gault equation.~7. Current need for hemodialysis or continuous renal replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin Loading (Type: EXPERIMENTAL): Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).